Decreased serum MG53 levels are associated with SHBG and androgen excess in women with polycystic ovary syndrome
Open Access
- 13 April 2026
- journal article
- Published by Springer Nature in Scientific Reports
- Vol. 16 (1)
Abstract
Polycystic ovary syndrome (PCOS) is a common endocrine disorder characterized by hormonal and metabolic abnormalities. Mitsugumin-53 (MG53), a multifunctional E3 ubiquitin ligase, is implicated in insulin signaling and oxidative stress regulation, yet its role in PCOS remains unclear. This study aimed to investigate serum MG53 levels in women with PCOS and explore their associations with hormonal, metabolic, and ovarian parameters. In this case–control study, 64 women with PCOS and 64 healthy controls with comparable age were enrolled. Serum MG53 concentrations were measured by ELISA. Associations between MG53 and continuous variables were assessed using Spearman’s rank correlation. Independent determinants of MG53 were evaluated using multivariable linear regression (including age and BMI as covariates), and diagnostic performance for PCOS was assessed using receiver operating characteristic (ROC) analysis. Serum MG53 concentrations were lower in women with PCOS than in controls (median [IQR]: 124.4 [104.25–202.15] vs. 206.4 [131.63–316.58] pg/mL; p = 0.001). MG53 correlated positively with sex hormone–binding globulin (SHBG) (ρ = 0.274, p = 0.002) and inversely with ovarian follicle count (ρ = − 0.223, p = 0.011). In multivariable analysis, SHBG remained an independent positive determinant of MG53, whereas hirsutism and follicle count were independent negative predictors. MG53 demonstrated modest discrimination for PCOS (AUC = 0.667, 95% CI 0.569–0.762), with 57.8% sensitivity and 75.0% specificity at an exploratory cut-off of 131.1 pg/mL. Serum MG53 is reduced in PCOS and is associated with SHBG and features related to androgen excess and ovarian morphology. These cross-sectional findings support MG53 as a candidate biomarker reflecting metabolic–reproductive associations in PCOS; however, its diagnostic performance is modest and requires external validation. Trial registration Prospectively registered on ClinicalTrials.gov (NCT07094776) as an observational study.Keywords
All Related Versions
This publication has 18 references indexed in Scilit:
- Overexpression of Annexin A1 Inhibits Pyroptosis and Improves Dry Eye Signs by Regulating the TRIM72/Nrf2/HO-1 Signaling PathwayArchivum Immunologiae et Therapiae Experimentalis, 2025
- Suppression of TRIM72‐mediated endoplasmic reticulum stress facilitates FOXM1 promotion of diabetic ulcer healingWound Repair and Regeneration, 2024
- MG53 does not mark cardiovascular risk and all-cause mortality in subjects with type 2 diabetes: A prospective, observational studyDiabetes Research and Clinical Practice, 2023
- Recommendations from the 2023 international evidence-based guideline for the assessment and management of polycystic ovary syndromeEuropean Journal of Endocrinology, 2023
- MG53 preserves mitochondrial integrity of cardiomyocytes during ischemia reperfusion-induced oxidative stressRedox Biology, 2022
- Glucose-Sensitive Myokine/Cardiokine MG53 Regulates Systemic Insulin Response and Metabolic HomeostasisCirculation, 2019
- Polycystic Ovary SyndromeObstetrics & Gynecology, 2018
- Scientific Statement on the Diagnostic Criteria, Epidemiology, Pathophysiology, and Molecular Genetics of Polycystic Ovary SyndromeEndocrine Reviews, 2015
- Central role of E3 ubiquitin ligase MG53 in insulin resistance and metabolic disordersNature, 2013
- Inflammation in Polycystic Ovary Syndrome: Underpinning of insulin resistance and ovarian dysfunctionSteroids, 2012